Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies

被引：3
作者：
Kevlicius, Lukas [1 ,2 ]
Cepulyte, Ruta [1 ]
Vasilevska, Dominika [2 ]
Griskevicius, Laimonas [1 ,2 ]
Zucenka, Andrius [1 ,2 ]
机构：
[1] Vilnius Univ Hosp Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania
[2] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / 06期
关键词：
D O I：
10.1038/s41409-022-01679-6
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1034 / 1037
页数：4
相关论文
共 15 条
  • [1] Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
    Borthakur, Gautam
    Popplewell, Leslie
    Boyiadzis, Michael
    Foran, James
    Platzbecker, Uwe
    Vey, Norbert
    Walter, Roland B.
    Olin, Rebecca
    Raza, Azra
    Giagounidis, Aristoteles
    Al-Kali, Aref
    Jabbour, Elias
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Bauman, John W.
    Wu, Yuehui
    Liu, Yuan
    Schramek, Dan
    Cox, Donna S.
    Wissel, Paul
    Kantarjian, Hagop
    [J]. CANCER, 2016, 122 (12) : 1871 - 1879
  • [2] Damnernsawad A, 2021, CANCER RES, V81
  • [3] Daver N, 2017, BLOOD, V130
  • [4] A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation
    Desikan, Sai Prasad
    Ravandi, Farhad
    Pemmaraju, Naveen
    Konopleva, Marina
    Loghavi, Sanam
    Borthakur, Gautam
    Jabbour, Elias J.
    Daver, Naval
    Jain, Nitin
    Chien, Kelly S.
    Maiti, Abhishek
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Kwari, Monica
    Kantarjian, Hagop
    Short, Nicholas J.
    [J]. BLOOD, 2021, 138
  • [5] Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
    DiNardo, C. D.
    Tiong, I. S.
    Quaglieri, A.
    MacRaild, S.
    Loghavi, S.
    Brown, F. C.
    Thijssen, R.
    Pomilio, G.
    Ivey, A.
    Salmon, J. M.
    Glytsou, C.
    Fleming, S. A.
    Zhang, Q.
    Ma, H.
    Patel, K. P.
    Kornblau, S. M.
    Xu, Z.
    Chua, C. C.
    Chen, Xufeng
    Blombery, P.
    Flensburg, C.
    Cummings, N.
    Aifantis, I.
    Kantarjian, H.
    Huang, D. C. S.
    Roberts, A. W.
    Majewski, I. J.
    Konopleva, M.
    Wei, A. H.
    [J]. BLOOD, 2020, 135 (11) : 791 - 803
  • [6] Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
    Han, Lina
    Zhang, Qi
    Dail, Monique
    Shi, Ce
    Cavazos, Antonio
    Ruvolo, Vivian R.
    Zhao, Yang
    Kim, Eugene
    Rahmani, Mohamed
    Mak, Duncan H.
    Jin, Sha S.
    Chen, Jun
    Phillips, Darren C.
    Koller, Paul Bottecelli
    Jacamo, Rodrigo
    Burks, Jared K.
    DiNardo, Courtney
    Daver, Naval
    Jabbour, Elias
    Wang, Jing
    Kantarjian, Hagop M.
    Andreeff, Michael
    Grant, Steven
    Leverson, Joel D.
    Sampath, Deepak
    Konopleva, Marina
    [J]. HAEMATOLOGICA, 2020, 105 (03) : 697 - 707
  • [7] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    [J]. HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [8] Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
    Maiti, Abhishek
    Naqvi, Kiran
    Kadia, Tapan M.
    Borthakur, Gautam
    Takahashi, Koichi
    Bose, Prithviraj
    Daver, Naval G.
    Patel, Ami
    Alvarado, Yesid
    Ohanian, Maro
    DiNardo, Courtney D.
    Cortes, Jorge E.
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Ravandi, Farhad
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (03) : 142 - +
  • [9] Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
    Ragon, Brittany Knick
    Odenike, Olatoyosi
    Baer, Maria R.
    Stock, Wendy
    Borthakur, Gautam
    Patel, Keyur
    Han, Lina
    Chen, Helen
    Ma, Helen
    Joseph, Loren
    Zhao, Yang
    Baggerly, Keith
    Konopleva, Marina
    Jain, Nitin
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (07) : 431 - +
  • [10] Therapeutic strategies to target RAS-mutant cancers
    Ryan, Meagan B.
    Corcoran, Ryan B.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (11) : 709 - 720
12